The LAMC1 antibody targets the laminin gamma-1 (LAMC1) protein, a key component of laminins—a family of extracellular matrix glycoproteins critical for basement membrane formation. Laminins, composed of alpha, beta, and gamma chains (e.g., LAMC1), provide structural support and mediate cell adhesion, migration, and signaling. LAMC1. encoded by the *LAMC1* gene, pairs with alpha and beta subunits (e.g., LAMA1. LAMB1) to form laminin-111 (formerly laminin-1), essential in embryonic development, tissue repair, and homeostasis. Dysregulated LAMC1 expression is linked to cancer progression, fibrosis, and genetic disorders like junctional epidermolysis bullosa.
LAMC1 antibodies are widely used in research to study basement membrane integrity, tumor microenvironment interactions, and metastatic pathways. They enable detection of LAMC1 via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Commercially available antibodies vary in specificity, host species (e.g., rabbit, mouse), and clonality (monoclonal/polyclonal). Validation steps, such as knockout controls, are crucial to confirm target specificity, as cross-reactivity with other laminin chains may occur. Recent studies highlight LAMC1's role in modulating cellular responses to mechanical stress and its potential as a therapeutic target in aggressive cancers.